Intec Pharma Ltd

Intec Pharma — Technical Presentation (March 2019)

16 slides from Intec Pharma's technical presentation, Mar 4, 2019

  1. Slide 1: TID PK Study

    TID PK Study Nasdaq : NTEC March, 2019

  2. Slide 2: Forward-looking statements disclaimer

    This presentation by Intec Pharma Ltd . (referred to as “we” or “our”) contains forward - looking statements about our expectations, beliefs and intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies, plans and prosp

  3. Slide 3: Continuous Dopaminergic Stimulation (CDS) Current Concepts

    • Fluctuating plasma levodopa levels lead to pulsatile stimulation of striatal dopamine receptors • Pulsatile stimulation of DA receptors causes: – Molecular changes in basal ganglia input neurons – Neurophysiologic changes in basal ganglia output neurons – Development of motor complications (motor

  4. Slide 4: Continuous Dopaminergic Stimulation (CDS) Current Concepts

    • It has been hypothesized that continuous delivery of levodopa will restore brain DA in a more physiologic manner • Open label and double blind studies confirm that the risk of motor complications is reduced if the same short - acting dopaminergic agent is delivered continuously rather than intermi

  5. Slide 5: Duodopa Study – Double-Blind, Double-Dummy, Double-Titration Study

    Duodopa ® Study – Double - Blind, Double - Dummy. Double - Titration Study Olanow et al, Lancet Neurol 2014 5

  6. Slide 6: Approaches to CDS in PD Patients

    Approaches to CDS in PD Patients • Continuous intrajejunal infusion • Continuous patch delivery • Continuous sc infusion • Continuous intraoral infusion • Oral drugs with long t1/2 6

  7. Slide 7: The Accordion Pill

    The Accordion Pill TM • Multi - layer, planar structure composed of biodegradable films folded into accordion shape placed into a standard size capsule 7

  8. Slide 8: Intec PK Study

    Intec PK Study • Open label cross - over PK study • 12 subjects • PD consistent with UK Brain Bank Criteria • On stable doses of standard oral levodopa • Day 1 – arrive in clinic in practically defined OFF state – Standard Levodopa PK • Day 2 - 7 – treated with AP – CD/LD 50/500 mg tid • Day 8 - arr

  9. Slide 9: Intec PK Study – Hospital Protocol

    Intec PK Study – Hospital Protocol • Day 1 – Levodopa PK - study – Standard Levodopa 1.5 25/100mg tabs vid (0, 3, 6, 9, 12 hours) • Day 8 – AP PK - study – AP - CD/LD (Levodopa) 50/500mg tid (0, 5, 10 hours) • PK evaluations – Q 30” from 0 to 16 hours, then at 24 hours 9

  10. Slide 10: Intec PK Study - Endpoints

    Intec PK Study - Endpoints • Primary Endpoint – Fluctuation Index ( C max - C min )/ C average ) in steady state (4 - 16 hours) • Sensitivity Analyses – Fluctuation Index (4 - 12 hours) – Fluctuation Index – Patients with Complete Data Set – Fluctuation index calculated by 2 hr time blocks (0 - 16 h

  11. Slide 11: Levodopa Concentration by Time (0-16 hours); Smoothed Splines by Group

    Levodopa C oncentration by Time (0 - 16 hours ); S moothed S plines by G roup L - dopa ng /ml 11

  12. Slide 12: Representative Patient

    tative Patient LDOPA (ng/mL) g 8 5 g 12

  13. Slide 13: Primary Endpoint: Fluctuation Index of Plasma Levodopa Concentration in Steady State

    Primary Endpoint : Fluctuation Index of Plasma Levodopa Concentration in Steady State 13

  14. Slide 14: Tolerability and Safety

    Tolerability and Safety • Tolerability – No drop outs • Safety – Day 1: IR - CD/LD PK day • Abdominal Cramps – mild • Diarrhea – mild • Fever • Panic attack – Day 8: AP - CD/LD PK day • No Adverse events reported 14

  15. Slide 15: Intec PK Study - Summary

    Intec PK Study - Summary AP - CD/LD met all primary, sensitivity and secondary endpoints • Primary Endpoint – Fluctuation Index P =0.005 • Sensitivity Analyses – FI - 0 - 12 hour steady state P =0.013 – FI - Completer Data Set P =0.015 – FI – 2 hour time blocks P =0.001 • Secondary Endpoint – Coeffi

  16. Slide 16: Conclusions

    Conclusions • Treatment with the Accordion Pill TM 50/500 mg tid resulted in reduced plasma levodopa variability in comparison to standard oral levodopa treatment • Clinical studies indicate that reduced variability in plasma levodopa is associated with a reduced risk of motor complications – PK is

Intec Pharma — Technical Presentation (March 2019) on 6ix